Skip to Navigation Skip to Search Skip to Content
Search All Centers

Coronavirus Live Ask the Expert Webinars

Coronavirus Live Ask the Expert Webinars
View next

Published on December 3, 2020

You have coronavirus questions and we have the experts. The hottest topics and answers to the questions you send in. Please join us for our series of live webinars or view the replay or transcript. We welcome your questions and suggestions anytime at comments@patientpower.info.

 

Upcoming Webinars

2020 0021E 02.PharmacyclicsHBI.CLL.AskMeAnything.LIVE.ASH.DrThompson.660x370

ASH 2020 CLL Ask Me Anything

Saturday 12/05/20 at 1:00 PM Pacific/ 4:00 PM Eastern

Join Patient Power on Saturday, December 5th at 1pm PT/4pm ET for a live Q&A with chronic lymphocytic leukemia (CLL) expert Dr. Philip Thompson! Don't miss this chance to ask a CLL doctor all of your questions and receive expert advice.

Dr. Thompson is part of the world's largest leukemia department at The University of Texas MD Anderson Cancer Center in Houston, Texas. He will be joined by Patient Power co-founder and patient advocate Esther Schorr. Dr. Thompson and Esther will also discuss the latest CLL news from the world’s most comprehensive hematology event of the year, the 62nd American Society of Hematology (ASH) Annual Meeting.

Do you have questions about CLL treatments, emerging research, or COVID-19's impact on your care? Ask your questions live or send them in advance to comments@patientpower.info.

This program is sponsored by Pharmacyclics. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.


2020 0070.GSK.MM.AnswersNow.ASH 2020.660x370

Live ASH 2020 Myeloma Answers Now

Sunday 12/06/20 at 2:00 PM Pacific/ 5:00 PM Eastern

Join Patient Power on Sunday, December 6th at 2:00 PM PT/5:00 PM ET for a live Q&A with multiple myeloma expert Dr. Joshua Richter! Don't miss this chance to ask a multiple myeloma doctor all of your questions and receive expert advice.

Dr. Richter is Assistant Professor of Medicine at the Tisch Cancer Institute at Mount Sinai School of Medicine. He has extensive clinical trial experience and has been published in the New England Journal of Medicine, Blood and the Journal of Clinical Oncology. He will be joined by Patient Power co-founder and patient advocate Esther Schorr. Dr. Richter and Esther will also discuss the latest multiple myeloma news from the world’s most comprehensive hematology event of the year, the 62nd American Society of Hematology (ASH) Annual Meeting.

Do you have questions about multiple myeloma treatments, emerging research, or COVID-19's impact on your care? Ask your questions live or send them in advance to comments@patientpower.info.

This program is sponsored by GlaxoSmithKline. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.


2020 0069 v2.GSK.MM.DailyWrap.ASH 2020.660x370 1

ASH 2020 Myeloma Daily Wrap-Up

Sunday 12/06/20 at 4:00 PM Pacific/ 7:00 PM Eastern

Join Patient Power on Sunday, December 6th at 4pm PT/7pm ET for a live recap of the latest MM (multiple myeloma) news from the 62nd ASH Annual Meeting. ASH is the world’s most comprehensive hematology event of the year where experts review thousands of scientific abstracts, highlighting updates on the most critical topics in hematology. Some of the field’s top doctors share their thoughts on emerging research, clinical trials, and how current events such as COVID-19 are impacting cancer patients. Attend live to hear exciting MM news from ASH 2020! 

This program is sponsored by GlaxoSmithKline. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.


2020 0064 02.CelgeneBMS.MPN.AskMeAnything.LIVE.ASH.DrMesa.660x370

ASH 2020 MPN Ask Me Anything

Monday 12/07/20 at 2:30 PM Pacific/ 5:30 PM Eastern

Join Patient Power on Monday, December 7th at 2:30pm PT/5:30pm ET for a live Q&A with MPN expert Dr. Ruben Mesa! Don't miss this chance to ask an expert all of your Myeloproliferative Neoplasm (MPN) questions!  

Dr. Ruben Mesa is the director of UT Health San Antonio MD Anderson Cancer Center. In Dr. Mesa's more than 20 years researching MPNs, he's built an international reputation as an expert on the subject. He will be joined by Patient Power co-founder and patient advocate Esther Schorr. Dr. Mesa and Esther will also be discussing the latest MPN news from the world’s most comprehensive hematology event of the year, the 62nd American Society of Hematology (ASH) Annual Meeting.

Do you have questions about MPN treatments, emerging research, or COVID-19's impact on your treatment? Ask your questions live or send them in advance to comments@patientpower.info.

This program is sponsored by BMS-Celgene. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.


2020 0064 01.Celgene.BMS.MPN.DailyWrap.ASH2020.660x370

ASH 2020 MPN Daily Wrap-Up

Monday 12/07/20 at 4:00 PM Pacific/ 7:00 PM Eastern

Join Patient Power Monday, December 7th at 4pm PT/7pm ET for a live recap of the latest myeloproliferative neoplasm (MPN) news from the 62nd American Society of Hematology (ASH) Annual Meeting. ASH is the world’s most comprehensive hematology event of the year, where experts review thousands of scientific abstracts, highlighting updates on the most critical topics in hematology. Many of the field’s top doctors will share their thoughts on emerging research, clinical trials and how current events such as COVID-19 are impacting cancer patients. Attend live to hear exciting MPN news from ASH 2020!

This program is sponsored by BMS-Celgene. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content. 


2020 0021E 01.HBI.Pharmacyclics.CLL.DailyWrap.ASH2020.660x370

ASH 2020 CLL Daily Wrap-Up

Tuesday 12/08/20 at 4:00 PM Pacific/ 7:00 PM Eastern

Join Patient Power on Tuesday, December 8th at 4pm PT/7pm ET for a live recap of the latest chronic lymphocytic leukemia (CLL) news from the 62nd American Society of Hematology (ASH) Annual Meeting. ASH is the world’s most comprehensive hematology event of the year where experts review thousands of scientific abstracts, highlighting updates on the most critical topics in hematology. Some of the field’s top doctors will share their thoughts on emerging research, clinical trials, and how current events such as COVID-19 are impacting cancer patients. Attend live to hear exciting CLL news from ASH 2020!

This program is sponsored by Pharmacyclics. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content. 


INT 2020 013 10 v2.MPN.IncyteMPNRF.AN.Nov11.660x370

How Do Racial and Socioeconomic Disparities Affect MPN Patients?

Wednesday 12/09/20 at 12:30 PM Pacific/ 3:30 PM Eastern

Join us for a discussion between our host, Ruth Fein, patient-advocate Taja Shabazz and  Dr. Irum Khan, Assistant Professor of Hematology/Oncology in the Department of Medicine at the University of Illinois College of Medicine on December 9th at 12:30 pm PT/3:30 pm ET.

Dr. Khan is passionate about caring for traditionally underserved patients every day and her research focuses on racial and socioeconomic disparities in treatment patterns and outcomes. Who is predisposed to scarring, bleeding, clotting? Where do institutions tend to fall short and how can they better to overcome barriers? How do disparities in access to care affect outcomes? And what can we, as an MPN community, do to advocate for all MPN patients to get the best care possible?

Get your questions answered live. Send them in ahead of the program to mpn@patientpower.info.

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.


INT 2020 013 14.MPN.IncyteMPNRF.AN.Dec16.660x370

New Clinical Trials for MPNs in 2021 and Beyond

Wednesday 12/16/20 at 2:30 PM Pacific/ 5:30 PM Eastern

There used to be a stigma surrounding participation in clinical trials. Moving into 2021, patients have a more nuanced understanding but questions remain: How will I be monitored? How will my care team change? How does Covid fit into all this?

Join us for a discussion among our host Ruth Fein, Dr. Gabriela Hobbs, active clinical researcher and leader of the MPN research program at Massachusetts General Hospital, and Dr. Angela Fleishman, Assistant Professor of Medicine at the Institute for Immunology at the University of California, Irvine on Wednesday, December 16th at 2:30pm PST/5:30pm PST. They’ll discuss clinical trials in the age of combination therapies, finding a clinical trial that may be right for you and more.

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.

Get your questions answered live. Send them in ahead of the program to mpn@patientpower.info.

  

Past Webinars

INT 2020 013 12 v2.MPN.IncyteMPNRF.AN.Dec2 AN 660x370

Weighing Decisions & Outcomes for MPN Stem Cell Transplants

Weighing all of the variables that are involved in considering a stem cell transplant – pros and cons of treatment, affordability, success rate – can feel suffocating. And that’s before the procedure itself! In this special installation of our MPN Answers Now series, our host Andrew Schorr SPOKE with patient advocate, Rabbi Ronald Roth and Dr. H. Joachim Deeg of the Seattle Cancer Care Alliance about transplant decision-making and outcomes.

What does this decision-making process entail? What should a transplant candidate do before and after the procedure? Is there research on the horizon that will change the calculus for patients in the coming years?

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.


2020 0058 03.CMI.AbbVie.CLL.AN.Event3.Nov23.660x370

Experts Answer Critical Questions on CLL Testing

Navigating the landscape of CLL testing can be overwhelming. What does your blood test result mean? Measurable Residual Disease (MRD) testing allows people to stop therapy, but how does that impact you? What trends can my test results reveal about my overall health?

Experts answered important questions about radiation, CT scans, MRI, bloodwork, and biopsy. Patient Power Co-Founder and CLL Survivor Andrew Schorr was joined by Dr. Susan LeCLair, (retd.) Chancellor professor, Department of Medical Laboratory Science at University of Massachusetts, and Dr. Adam Kittai, Hematologist at OSU Comprehensive Cancer Center, for this expert panel.

This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content. 

  

2020 0058 02.CMI.AbbVie.CLL.AN.Event2.Nov19.660x370

Choosing A CLL Treatment to Match Your Lifestyle and Needs

Whether you have been newly diagnosed with CLL or are returning for further treatment, it can be overwhelming to research and choose a CLL treatment pathway. With factors such as cost, side effects, usage, and now with multiple treatment options to choose from, how do you choose the right and most effective treatment to continue living your life the way you want?

Patient Power Co-Founder and CLL Survivor Andrew Schorr was joined by Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute, and Dr. Catherine Callaghan Coombs, Assistant Professor at UNC School of Medicine as they discussed the different CLL treatment options and how to create the best treatment pathway to achieve your health and life goals.

This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content. 

  

2020 0059 01.Blueprint.LC.RET.AN.Nov6.660x370

New Targeted Therapies for RET Gene in Lung Cancer

The majority of lung cancer patients have non-small cell lung cancer (NSCLC), and a small percentage of those patients have the RET gene, also called RET fusion-positive lung cancer. What is the RET gene mutation, and how is it treated? We have information that is hot off the research presses on the newest targeted therapies.

During this lung cancer Answers Now program, our host talked to Dr. Viola Zhu from University of California at Irvine and Dr. Karen Reckamp, Director of Medical Oncology at Cedars-Sinai Cancer about the RET gene and new treatment options for patients with metastatic RET fusion-positive NSCLC.

This program is sponsored by Blueprint Medicines. This organization has no editorial control. It is produced by Patient Power, and Patient Power is solely responsible for program content.

  

INT 2020 013 13.MPN.IncyteMPNRF.AN.Nov18 660x370 AN

What Women with MPNs Need to Know

Does sex affect the way that people present MPNs? In some ways, yes. Women are more likely to have ET than PV or MF. And while the standard course of treatment can be identical for men and women, there are specific considerations for women.

Listen to a discussion about the cutting-edge research into sex and MPNs and how women can manage their care team in a way that supports their reproductive health whether they're 25 or 65. Our host Ruth Fein talked to Dr. Ellen Ritchie, Assistant Professor of Medicine and a member of the Leukemia Program at the Weill Cornell Medical College of Cornell University and the New York Presbyterian Hospital in New York City.

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.

  

 prostate cancer outcomes

How to Manage Prostate Cancer Side Effects and Reduce Suffering

Talking honestly about one’s medical realities in the doctor’s office takes practice, but it is a crucial step to take. Watch as experts discussed how transparent doctor-patient relationships can improve prostate cancer outcomes.

In the final segment of our prostate cancer Answers Now series, our patient host spoke with Dr. Atish Choudhury, Co-Director of the Prostate Cancer Center at Dana-Farber Cancer Center about the importance of open communication between patients and physicians. What are the best treatment options? What side effects may I experience? What will my quality of life be? Expect all of these answers and more.

This program is sponsored by Bayer. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

2020 0058.AbbVie.CMI.CLL.AN.Event1.Nov12.660x370

Sinus and Respiratory Infections for CLL Patients During COVID

Cold and flu season is approaching, and for those with chronic lymphocytic leukemia (CLL), the increased risk of sinus and upper respiratory infections during this time can rightly warrant extra precaution. This year, that is paired with entering flu season during a worldwide pandemic. Listen in as a team of experts shared important tips for staying safe and healthy in the months to come.

Patient Power Co-Founder and CLL Survivor Andrew Schorr will be joined by Co-Host and Patient Advocate Michele Nadeem-Baker as they interview Dr. Stacey Gray, Director, Sinus Center at Massachusetts Eye and Ear, on how to navigate cold and flu season as a CLL patient.

This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

INT 2020 013 11.MPN.IncyteMPNRF.AN.Nov4 AN 660x370

Can Telemedicine Improve the Quality of Your MPN Care?

The Coronavirus pandemic forced an explosion in telemedicine where many people see their MPN doctor on a screen rather than in an exam room. Is it just as good? Without your doctor touching you are they really able to provide quality care?

What does this mean for how MPN patients will receive clinical care moving forward? What will the trade-offs be, if any?

We will cover these topics to help viewers navigate the virtual world of healthcare, and ideally maintain the quality of their doctor-patient relationships. Our host talked to Dr. Aaron Gerds, Deputy Director for Clinical Research at Taussig Cancer Institute, Associate Professor of Medicine, physician and MPN expert, about the role telemedicine and technology will play in MPN treatment moving forward.

This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

2020 0053 02.Bayer.Prostate.AN.Nov6.660x370

PSA and Imaging for Prostate Cancer Patients

In this edition of our prostate cancer Answers Now series, we learned about the latest in testing and imaging for prostate cancer with hosts & AnCan Prostate Cancer Moderators, Len Sierra and Peter Kafka. Patient Power Founder and patient-advocate Andrew Schorr served as the emcee during the discussion. They were joined by Scott Tagawa, MD, Professor of Medicine and Urology at NewYork-Presbyterian-Weill Cornell Medical Center in New York City and David VanderWeele, MD, PhD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine. We covered what PSMA PET and Next Generation Imaging can mean for patients at different points in their prostate cancer journey.
 
This program is sponsored by Bayer. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
  

INT 2020 013 09.MPN.IncyteMPNRF.AN.Nov4 660x370

MPNs in Children, Teenagers, and Young Adults

While most myeloproliferative neoplasm (MPN) patients are older adults, children and young adults can be affected as well, and research & treatment for pediatric MPNs is a growing field. Find out what we know and hope to discover about MPNs in children with our host Ruth Fein, patient advocate Portia Pliam, and special guest Dr Nicole Kucine, who specializes in pediatric MPNs as Assistant Professor of Pediatrics at Weill Cornell Medicine.

How do you diagnose MPNs in children and young adults? What treatment options are available? Do they differ from treatments for adults with MPNs? What are the unique challenges of this rare pediatric condition? And finally, what does the future look like for children with MPNs? 

This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

her2 negative and her2 positive breast cancer

Everything You've Always Wanted to Know About HER2

HER2 has been a major part of the breast cancer vocabulary since the 1980s. Nowadays everyone knows their status as a matter of course. But what exactly does that mean? 

Dr. Sara Hurvitz, Director, Breast Cancer Clinical Trial Program at UCLA Medical Center, and patient advocate and writer Andrea Hutton talked about HER2 in depth. Whether you’re positive or negative, this discussion helped clarify what we know about human epidermal growth factor receptor 2 and how emerging research is changing our understanding of these proteins and, in turn, the treatment options for breast cancer patients of all stripes.

This program is supported by an educational grant from Daiichi Sankyo. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content.

  

lungcancer

Immunotherapy For Lung Cancer Brings Treatment Breakthroughs

Immunotherapies have radically changed treatment for non-small cell lung cancer (NSCLC) patients. In fact, the PD-L1/PD-1 blockade is a bona fide breakthrough. What does this fast-moving course of research and treatment mean for lung cancer patients of all persuasions? 

Watch as host and patient advocate Lisa Goldman talked to Dr. David Carbone of the Ohio State University about existing PD-L1/PD-1 treatment options and those currently in development.

  

thumbnail 2 v2

Prostate Cancer and Making Sense of nmCRPC Treatment Options

In 2018, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) were watching and waiting. Two years later there are three novel androgen receptor inhibitors available. But more options mean more questions for doctors and for patients. In this first installment of our prostate cancer Answers Now series, we explored these emerging questions around who should use what when, and why. We gave an overview of the disease and current treatment options. Our Patient Power host will talk to Dr. Eleni Efstathiou from MD Anderson Cancer Center in Texas and Dr. Tom Beer, Chair of Prostate Cancer Research at OSHU. 

 

This program is sponsored by Bayer. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

What is MPN

The Road to Curing MPNs

Host and Patient Advocate Ruth Fein talked to physician-scientist Dr. Ross Levine of the Memorial Sloan Kettering Cancer Center about his research on myeloproliferative neoplasms (MPN) blood cancers.

Dr. Levine’s research focuses on the “somatic mutations in hematologic malignancies using candidate gene, genome-wide, and functional approaches” in MPN. We talked to him, in a way that everybody can understand, about what that means for patients now and for the future of MPN treatment. Also, we talked about the role of “aberrant signal transduction in malignant transformation and in the effects of mutations in epigenetic modifiers.”

This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

2020 0039D.HavasSanofiGenzyme.MMY.AN.Oct22.660x370

What If I Become Resistant to Lenalidomide (Revlimid)?

One of the backbones of the myeloma treatment regimen is lenalidomide (Revlimid). But what happens when a myeloma patient becomes resistant to this widely used oral drug? 

Host Cindy Chmielewski talked to myeloma expert Dr. Craig Cole of Michigan State University Breslin Cancer Center about treatment options for "life after Revlimid". 

This program is sponsored by Sanofi Genzyme. This organization has no editorial control, and Patient Power is solely responsible for program content.

  

INT 2020 013 07.MPN.IncyteMPNRF.AN.Oct21.660x370

In Covid Times, What's a Transfusion or Phlebotomy Dependent MPN Patient To Do?

Having to account for the logistical, emotional, and medical ramifications of COVID-19 is enough to drive anyone batty. For patients who are transfusion or phlebotomy dependent, the burden is even higher.

In this week’s Answers Now: Facing MPNs our intrepid advocate-host Ruth Fein talked to Dr. John Mascarenhas, professor at Icahn School of Medicine and director of the Adult Leukemia Program at Mount Sinai, about life for transfusion or phlebotomy dependent patients.

This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

MK 2020 124B 11.MM.AN.CART.Oct16.660x370

Latest News on CAR T-Cell Therapy for Multiple Myeloma

How can CAR T-cell therapy be used to treat multiple myeloma? Is it getting closer to being an approved treatment option? Watch as host and patient advocate Cindy Chmielewski talked to expert Dr. Sergio Giralt from Memorial Sloan Kettering Cancer Center. 

  

INT 2020 013 06 v2.MPN.IncyteMPNRF.AN.Oct14.660x370

What Genetic Markers Mean for Your MPN Care

Remember 2005? It’s the year three 20-somethings founded YouTube and the highest grossing movie featured a child wizard. It’s also the year that the JAK2 V617F mutation was discovered. In the intervening decade and a half, the understanding of that genetic marker, and the discovery of subsequent mutations, has radically changed our understanding of MPNs.

So, you know your markers. What does this mean for your care? Patient and journalist Ruth Fein coveredred translating genomics and prognostic models into everyday practices on this Answers Now: Facing MPNs program.

This program is sponsored by Incyte and is produced in partnership with the MPNRF. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

INT 2020 013 05.MPN.BMSInrebic.AN.Oct7.660x370

Creating A Sustainable Support Network for MPN Patients

Having an MPN can be isolating. So can caring for someone with an MPN. Host Esther Schorr  who has been a dedicated care partner for nearly a decade  explored the role that friends and family can play in supporting an MPN patient while continuing to take care of themselves. What role can research, planning, and advocacy play in being a successful source of support? How can care partners build their own support networks so that they can remain supportive in the long term?

This program is sponsored by Bristol Myers Squibb. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

2020 0049 03.DaiichiSankyo.BC.AN.Oct3.660x370

Learning About Estrogen Receptor-Positive (ER+) Breast Cancer Treatments

What treatments are available for estrogen receptor-positive (ER+) breast cancer patients? Are there breast cancer clinical trials that could help? How can patients manage side effects?

 Patient advocate host discussed ER+ treatments with expert Dr. Erika Hamilton from Sarah Cannon Research Institute. They were also joined by a breast cancer patient advocate to discuss their journey.

This program is supported by an educational grant from Daiichi Sankyo. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content. 

  

INT 2020 013 04.MPN.IncyteMPNRF.AnswersNow.Sept30.660x370

The Leading Edge of MPN Treatment

The tide of new information can be overwhelming. Hosts, Andrew Schorr & Ruth Fein, talked to Dr. Srdan Verstovsek, Professor of Medicine and a hematologist-oncologist at The University of Texas MD Anderson Cancer Center, about recent research leading to new therapies and new understandings of myeloproliferative neoplasms (MPNS) including detailed information about potential new treatments for essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). As a number of clinical trials move through Phase Three, there are new therapies and more FDA approvals are on the horizon. There are many new treatment options to get excited about.

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.

  

INT 2020 013 03.MPN.IncyteMPNRF.AnswersNow.Sept23.660x370

Watching, Waiting and Decision-Making with MPNs

In the immortal words of Tom Petty, “the waiting is the hardest part.” When it comes to MPNs, making decisions around when to start a specific treatment are difficult. 

In this installment of Answers Now: Facing MPNs, patient-advocate host Ruth Fein talked to Dr. Gabriela Hobbs, Clinical Director of Leukemia Service at Mass General, about the pros and cons of watch and wait. Which factors should be included in the process and how should those factors be weighted? Medical history?  Symptoms?  Blood numbers? Timed treatments? We also heard from a patient about her experience.

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.

  

2020 0021C 07.PharmJan.CLL.AN.Sept16.660x370

Telling Others About My CLL Diagnosis

How do you tell family and friends that you have leukemia? Chronic Lymphocytic Leukemia (CLL) patients often don't "look sick" so it may be hard for your family, friends and co-workers to know what you are going through. How do you help others understand your condition?

Host and CLL patient Michele Nadeem-Baker discussed with social worker Robin Katz from Lurie Cancer Center of Northwestern University communication tips for people living with CLL, and the best way to share details of their condition. 

This is a sponsored program where organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

INT 2020 013 02.MPN.BMSInrebic.AN.Sept16.660x370

PV, ET and MF: Experts Explain What to Worry About

Rare blood cancers are tricky for doctors to recognize. So how does a patient begin to wrap their head around such a disease? 

In this installment of Facing MPNs Answers Now, Host Ruth Fein, who has had all three types of MPN over the course of 25 years, dove into the three types of myeloproliferative neoplasms: essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). We addressed common questions MPN patients have when they're newly diagnosed and the questions doctors wish people would ask to set themselves up for successful management and self-advocacy over the long term. Watch as our host discussed these issues with Dr. Michael J. Mauro of Memorial Sloan Kettering Cancer Center and Dr. Abdulraheem Yacoub of The University of Kansas Cancer Center.

This program is sponsored by Bristol Myers Squibb. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

MK 2020 110B 07.Unsp.NavCan.Workplace.AN.Sept11.660x370

Cancer In The Workplace: Do I Have To Tell My Boss?

The recent death of Black Panther star Chadwick Boseman from colon cancer shocked the world, including his co-stars and directors. Boseman chose not to disclose his 4 year cancer battle, which included surgeries and chemotherapy. Had his cancer diagnosis and treatments been public, would that have changed his career path? For most of us, whether to share a cancer diagnosis and treatment to our employers is a big decision. What are our legal rights? What happens to our work if we disclose our cancer? What if we choose to keep our health information private?

Dr. Mark Lewis, a practicing Utah oncologist living with cancer, Jill Silverstein, employment and civil rights attorney and Esther Schorr, host and patient advocate, answered questions about cancer and the workplace. 

  

MK 2020 124B 10.MM.AN.Transplant.Event.660x370

When Is A Stem Cell Transplant Necessary to Treat Myeloma?

Is a stem cell transplant right for me? How and when does a stem cell transplant fit into treating myeloma? With all the new advances in myeloma treatments, are stem cell transplants still performed as often?

Host and 3-time stem cell transplant survivor, Jack Aiello sat down with multiple myeloma expert, Dr. Amrita Krishnan from City of Hope to discuss these questions. 

  

2020 0045 03.MPN.BMS.AnswersNow.Sept7.660x370

Managing MPN Anxiety During COVID-19

Having a myeloproliferative neoplasm like essential thrombocythemia (ET), polycythemia vera (PV) or myelofibrosis (MF) is anxiety producing enough, now add the stress of COVID-19, and many people find their anxiety is through the roof. Are there ways people can cope with the added stress and find ways to calm down all while still getting the treatment you need?

Host and MPN patient Andrew Schorr discussed these issues with counseling psychologist, Dr. Jim Healy.  He knows the MPN perspective all too well because his wife, Madonna has been living with polycythemia vera (PV) for over 10 years. 

This program is sponsored by Bristol Myers Squibb. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content. 

  

2020 0042 03.Sierra.MPN.AN.Sept4.660x370

What's My Risk for MPN Disease Progression?

What's the risk of a myeloproliferative neoplasm (MPN) progressing to another type of MPN or even to acute myeloid leukemia (AML)? Host Andrew Schorr who is living with myelofibrosis, joined Dr. Olatoyosi Odenike of the University of Chicago Medicine to discuss the risk factors that lead to MPN disease progression. 
 
This program is sponsored by Sierra Oncology. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for the program content.
  

2020 0049 02.Daiichi.Sept1.TripleNeg.Sept1.660x370

Triple Negative Breast Cancer Treatment News

What treatments are available for triple negative breast cancer patients? Are there triple negative breast cancer clinical trials that could help? How can patients manage triple negative breast cancer chemo side effects? 

Patient advocate host Ricki Fairley discussed triple negative breast cancer treatments with expert Dr. Sara Tolaney from Dana-Farber Cancer Institute about these important treatment questions. Send your questions for the expert in advance to breast@patientpower.info.

This program is supported by an educational grant from Daiichi Sankyo. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content. 

  

2020 0036 04.AbbvieGenentech.CLL.AN.August27.660x370

Aggressive CLL Treatment Options: Are They Right for Me?

How do experts decide when a CLL patient needs more aggressive treatments? In the age of oral therapy, when do CLL treatments such as CAR-T therapy and clinical trials make sense? Host Andrew Schorr spoke with University of Rochester Wilmot Cancer Center's Dr. Paul Barr on these more aggressive treatment options for CLL. 
 
This program is sponsored by AbbVie, Inc. and Genentech, Inc.  These organizations have no editorial control. It is produced by Patient Power.  Patient Power is solely responsible for program content.
  

MK 2020 121B 04.Unsp.Lung.KRAS.AN.Aug26.660x370

KRAS Lung Cancer Treatment News

What's the latest treatment news for lung cancer patients with the KRAS (Kirsten rat sarcoma viral oncogene homologue) mutation?

Terri Conneran, host and founder of the KRAS Kickers Support Group, WAS joined by lung cancer experts, Dr. Jyoti Patel from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Dr. Jessica Lin from Harvard Medical School. 

  

2020 0037 04.Incyte.MPN.SideEffects.AN.Aug20.660x370

Managing Side Effects of MPN Treatment

Myeloproliferative neoplasms (MPNs) can have symptoms that reduce quality of life and it’s not uncommon for treatments to have bothersome or even serious side effects that may reduce quality of life. How can you and your doctor work together to manage these?

Host Andrew Schorr talked to MPN experts from The University of Texas MD Anderson Cancer Center, Dr. Naveen Pemmaraju and Physician Assistants Rodney Haltom and Julie Huynh-Lu on the various side effects of MPN treatments and how to get relief. They covered side effects including itching, fatigue, and many more. 

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for the content.

  

2020 0017A 3.AbbvieGenentechAdapBio.CLLATE.Event.Aug12.660x370

CLL Expert: Ask Me Anything!

Do you have chronic lymphocytic leukemia questions to ask? During this CLL Ask The Expert Program, host Andrew Schorr spoke with CLL expert Dr. Richard Furman from Weill Cornell Medicine to answer the latest CLL questions related to treatment and news. 

This program is sponsored by AbbVie, Inc., Genentech, Inc. and Adaptive Biotechnologies. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

  

MK 2020 109B 37.ExerciseDuringCOVID 19.AN.Aug11.660x370

Exercising Safely During COVID-19

Esther Schorr joined avid runner Kenny Capps, who is living with multiple myeloma, and cancer exercise specialist Cathy Skinner from Thrivors, Inc. They discussed how cancer patients can stay active while in quarantine, online resources and creative at-home objects that can be used for exercise. 

  

2020 0045 02.BMS.MPN.Aug3.660x370

New Treatments For Essential Thrombocythemia

What new essential thrombocythemia (ET) treatment options, including clinical trials and drug approvals, are available? Are there delays in treating ET because of COVID-19? What diet or supplements work for managing essential thrombocythemia? 
 
Host Andrew Schorr talked to MPN expert Dr. Ellen K. Ritchie from Weill Cornell Medicine
  
This program is sponsored by Bristol Myers Squibb. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content. 
  

MK 2020 124B 09.Unsp.MM.AN.Aug7.660x370

Managing Side Effects of New Myeloma Drugs

Multiple Myeloma patients have more treatment options than ever before but how are side effects and toxicities managed? 

Host and patient advocate Cindy Chmielewski talked to Dr. Cesar Rodriguez from Wake Forest Baptist Health and Dr. Natalie S. Callander from the University of Wisconsin School of Medicine and Public Health about new myeloma drugs like belamaf, ide-cel, CAR-T, and selinexor. They also discussed how experts are managing toxicities from these new treatment options. 

  

2020 0049 01.BCAnswersNow.Aug4.660x370

Breast Cancer Care During COVID-19

Are breast cancer patients in treatment affected by the COVID-19 pandemic? Is surgery, radiation or chemotherapy delayed? How can patients find support during this socially distant time? 
  
Our patient advocate host, Megan-Claire Chase got answers from breast cancer oncologist, Dr. Shaveta Vinayak from Seattle Cancer Care Alliance, radiation oncologist, Dr. Catherine Park from UC San Francisco and Director of Breast Cancer Surgery, Dr. Freya R. Schnabel from NYU Langone's Perlmutter Cancer Center. Metastatic Breast Cancer Patient Advocate, Shonte Drakeford also shared her story and concerns. 
  
This program is supported by an educational grant from Daiichi Sankyo. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content. 
  

2020 0036 03.AbbVieGenentech.CLLAnswersNow.July31.660x370

CLL Patients and COVID-19: What's My Risk?

People living with chronic lymphocytic leukemia may be unsure about their risk of getting the coronavirus and developing severe complications. Dr. Anthony Mato, a renowned CLL specialist at Memorial Sloan-Kettering in New York City, has been compiling data from treatment centers around the world.
  
Dr. Mato discussed what we know so far about the risks of COVID-19 for people living with CLL. Also, we heard from CLL patient Heidi Yates who shared her experience of recovering from COVID-19. 
  
This program is sponsored by Abbvie, Inc. and Genentech, Inc.  These organizations have no editorial control. It is produced by Patient Power.  Patient Power is solely responsible for program content.

MK 2020 121B 03.Unsp.EGFRLungCancerAN.July29.660x370Epidermal Growth Factor Receptor (EGFR) Lung Cancer News

Host Andrea Hutton and lung cancer experts Dr. Bruce Johnson from Dana-Farber Cancer Institute and Dr. Alex Spira from Virginia Cancer Specialists discussed the latest treatments and COVID-19 updates for EGFR lung cancer patients.
 
They were also joined by EGFR patient advocates Jill Feldman and Mike Smith who shared their stories and concerns. 

ALL.Unsp.PedALL.AnswersNow.July23.MK 2020 112B 01.660x370Latest News For Treating Pediatric Acute Lymphoblastic Leukemia

What's the current status on treatments for pediatric acute lymphoblastic leukemia and what new treatment options are on the horizon? 
 
Host Andrew Schorr spoke with pediatric ALL specialist, Dr Allison Grimes from UT San Antonio Health. They discussed precautions to take during the COVID-19 pandemic along with updates on acute lymphoblastic leukemia treatments, including BiTE and CAR T-Cell therapy. A pediatric ALL patient and their parents also attended the program and shared their stories.

2020 0042 02.SierraMPNRF.MPNAnswersNow.July24 660x370 1

Would I Be a Good Candidate for an MPN Clinical Trial?

What MPN questions are researchers answering through clinical trials? Why might someone with an MPN want to consider a clinical trial? Are pharmaceutical companies offering any financial assistance for their trials? 
 
Host Andrew Schorr discussed these questions with MPN expert Dr. Christopher Hillis from Juravinski Cancer Centre in Ontario, Canada, and Dr. Barbara Klencke, Chief Development Officer at Sierra Oncology. An MPN patient also shared their experience. 
 
This program is sponsored by Sierra Oncology. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for the program content.

thumbnail 2

CLL Survivors Share their CAR-T Cell Experiences

CAR-T Cell therapy is a potential treatment for people living with CLL. Even if you are unsure if CAR-T is right for you, it's a good idea to understand the latest information as well as pros and cons should you face that decision in the future.

Andrew Schorr talked to expert Dr. Nitin Jain from the University of Texas MD Anderson Cancer Center. They were joined by patient advocates, David Garcia and Larry Saltzman who shared their own CAR-T cell experiences. The panel also discussed if you can get CAR-T cell therapy during the COVID-19 pandemic. 

MPN. Incyte.AnswersNow.June 9.2020 0037 03.660x370

Polycythemia Vera and Clotting: Does COVID-19 Make Me High Risk?

Are polycythemia vera (PV) patients at a higher risk during the coronavirus pandemic? Should they worry about clotting, strokes, or even hospital capacity to treat them?
 
Host Esther Schorr talked with two MPN experts, Dr. Angela Fleischman from UC Irvine and Dr. Joseph Scandura from Weill Cornell Medicine. They were joined by a PV advocate to share their experience and their concerns. 
 
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for the content.

NavCan.AnswersNow.Event1.July7.MK 2020 109B 36.660x370

Expert Advice on Managing Side Effects of Cancer Treatment

Cancer, along with the side effects from treatments, is a formidable foe. Palliative care is a means of managing fatigue, pain, nausea, sleeplessness and more. 

Often confused with hospice care, palliative care is finally receiving the attention it deserves. From mitigating side effects to improving overall quality of life, it has become an integral part of cancer care. Dr. Subbiah Ishwaria, a leading expert from the University of Texas MD Anderson Cancer Center, and patient advocate Stacey Tinianov, discussed the benefits of palliative care and explain how to incorporate it into your treatment plan.


CLL.AbbVieGenen.July3.2020 0036 02.660x370

Managing the Costs of CLL Treatment

CLL treatment can be expensive, particularly over time and when it's treated like a chronic condition. Is there a benefit to fixed duration therapy? Does it keep costs down? Are there financial resources available to help?

Host Andrew Schorr talked to CLL expert Dr. Thomas Kipps of UC San Diego Moores Cancer Center and Dr. Jennifer A. Woyach of The Ohio State University about where cost concerns come into play when making treatment decisions. They were joined by a patient advocate.

This program is sponsored by AbbVie, Inc. and Genentech, Inc.  These organizations have no editorial control. It is produced by Patient Power.  Patient Power is solely responsible for program content


A Cancer Patients Guide To Masks

A Cancer Patient's Guide To Masks

What types of masks are available and offer the best protection for cancer patients against COVID-19? Host Esther Schorr talked to advanced practice nurse Summer Krain, from the UAMS Myeloma Center, on what she is advising her patients to wear. They were joined by a patient advocate who shared their experience. 

CLL.JanPharm.CLLAnswersNow.Event5. June 18.2020 0021C 05.660x370

Will COVID-19 Influence CLL Care Long Term?

The recent coronavirus pandemic temporarily disrupted plans for many, but will it shift the thinking of chronic lymphocytic leukemia (CLL) treatment forever? Host and 20+ year CLL patient Andrew Schorr talked to leading expert Dr. Nitin Jain from The University of Texas MD Anderson Cancer Center and Dr. Alexey Danilov from City of Hope along with another long-term CLL survivor.

Although this is a sponsored program, Patient Power maintains editorial control and is solely responsible for the content of this program.


mpn answers now 660x370

The Future of MPN Research After COVID-19

With the coronavirus pandemic, has research on myeloproliferative neoplasms (MPNs) halted? Are clinical trials still moving forward? For our latest Answers Now program, host and MPN patient Andrew Schorr talked to two MPN researchers, Dr. Naveen Pemmaraju of the University of Texas MD Anderson Cancer Center and Dr. Jeanne Palmer of the Mayo Clinic Arizona.

This program is sponsored by Sierra Oncology. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for the program content.


Nav.Unsp.AnswersNow.June11.MK 2020 109B 32.660x370

An Honest Conversation About Masks and COVID-19

What should you say to others about why you're wearing a mask during this coronavirus pandemic?

Breast cancer survivor Greta Beekhuis was hassled in a store parking lot when she wore a mask to pick up her medicine. Greta shared her story and what she wishes she would have said that day. Lung cancer patient Gina Hollenbeck wore a mask to the gym and then posted a photo of herself on social media, along with her reasoning behind it. She shared her experience about backlash she received.

Social work program manager Harold Dean from UAMS Myeloma Center provided guidance for how, or if, to have those difficult conversations with family, friends, neighbors and people you encounter.


AnswersNow MMY KOL ASCO Header 660x370

Latest Myeloma Treatment News From ASCO

Where can you put 50 years of myeloma patient wisdom to work for you so you or a loved one gets the best care? Where? On Patient Power’s Myeloma Answers Now program, FOUR very experienced patients/support leaders gave their perspectives on myeloma news from ASCO, the world’s largest cancer medical meeting. They explained and took questions on what you should talk to your doctor about.


Financial Answers Now

Is Financial Help Available If I Lost Income Due to COVID-19?

Navigating the costs of cancer care can be daunting enough but what if you have a change in income due to the coronavirus pandemic? That change in income can impact programs you might be enrolled in like Medicaid and Medicare along with co-pay assistance programs. Andrew Schorr led our Answers Now program as he talked to two leading financial navigators, Dan Sherman  and Aimee Hoch, on how to deal with these changes and resources that can help.

This is a sponsored program where organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.


CLL Answers Now

Should I Delay CLL Treatment Because of the Coronavirus Pandemic?

Should you delay CLL treatment because of the coronavirus? Whether this is your first treatment or if you need re-treatment after coming out of remission, this is an important question to get answered! What are the pros and cons of initiating or delaying treatment?

Host and CLL patient advocate Andrew Schorr got the answers from CLL experts Dr. Philip Thompson from the University of Texas MD Anderson Cancer Center and Dr. John Allan from Weill Cornell Medicine. CLL patient advocate Jeff Folloder also joined to share his patient perspective.

This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power.  Patient Power is solely responsible for program content.


2020 0037 02 MPN AnswersNowCOVID19Testing Header 660x370 v4

COVID-19 Testing for MPN Patients

Myeloproliferative neoplasm patients want to know if they can get tested for COVID-19, if they can trust the test results and if their MPN affects the results. Host and MPN patient Andrew Schorr got the facts from MPN experts, Dr. Brady Stein from Lurie Cancer Center in Chicago and Dr. Ellen Ritchie from Weill Cornell in NYC. They were joined by MPN patient advocate and Dr. Ritchie's patient, Ruth Fein who shared her experience with COVID-19 symptoms.

This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.


MK 2020 109B 29 AnswersNow COVIDTesting Header 660x370 1

The Latest in Blood and Antibody Tests for COVID-19

We are learning more about antibody tests for COVID-19. Host Andrew Schorr led our follow-up session with noted laboratory science experts Susan Leclair, PhD, and Jim Griffith, PhD.


2020 0021C 04 CLL AnswersNowCoronavirusRisk Header 660x370

What's My Current Risk for Coronavirus?

What's the latest data on my risk of getting the coronavirus and the complications that could come from it as a CLL patient? Host Andrew Schorr spoke live with Dr. Matthew Davids from Dana-Farber Cancer Institute about his experience treating patients in Boston. They were joined by CLL patient advocate Michele Nadeem-Baker who shared her patient perspective.

Although this is a sponsored program, Patient Power maintains editorial control and is solely responsible for the content of this program.


Cancer and COVID 19 When Will I Be Safe

Cancer and COVID-19, When Will I Be Safe?

Throughout the country, states are “opening up” amidst the coronavirus pandemic. What do cancer patients and other immunocompromised individuals need to know? Andrew Schorr talked to two experts from Sarah Cannon Research Institute at Tennessee Oncology.


2020 0039A MMY AnswersNowMakingSenseNewTreatmentsDuringCoronavirus 1200x800

Making Sense of New Myeloma Treatments During Coronavirus

Amidst the coronavirus pandemic, new myeloma medicines are still being approved. How do patients and their doctors incorporate these new therapies during this time of telemedicine and adjusted treatment schedules? Dr. Saad Usmani from Levine Cancer Institute and leading patient advocate Jack Aiello joined us to discuss. 

This program is sponsored by Sanofi Genzyme. This organization has no editorial control. Patient Power is solely responsible for program content.


What Do MPN Patients Need to Know About COVID 19

What Do MPN Patients Need to Know About COVID-19?

We continue to learn what COVID-19 means for MPN patients from top experts. Two experts from leading centers, Dr. Raajit Rampal from Memorial Sloan Kettering in New York City, and Dr. Srdan Verstovsek from MD Anderson in Houston, answered audience questions and explained the latest research. Michelle Woehrle, from the MPN Research Foundation also joined with an update on resources that can help. 


Spirituality Mindfulness and Gratitude in the Time of the Coronavirus

Spirituality, Mindfulness and Gratitude

Two spiritual leaders - Rabbi Jill Zimmerman and Pastor Rodrick Echols - joined us to discuss how to tap into your individual version of spirituality, mindfulness and gratitude as we all face this trying time of the coronavirus pandemic.

View next